Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

SURESH GUPTA MD INC

NPI: 1508895640 · DAYTON, OH 45432 · Pain Clinic/Center · NPI assigned 07/01/2006

$8.41M
Total Medicaid Paid
230,395
Total Claims
213,078
Beneficiaries
50
Codes Billed
2018-01
First Month
2024-12
Last Month

Provider Details

Authorized OfficialGUPTA, SAPNA (CHIEF LEGAL OFFICER)
NPI Enumeration Date07/01/2006

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 52,928 $1.10M
2019 49,813 $1.19M
2020 48,352 $1.20M
2021 24,359 $1.33M
2022 20,486 $1.18M
2023 17,750 $1.32M
2024 16,707 $1.10M

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 44,854 41,249 $1.92M
36475 1,447 849 $1.53M
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 9,898 9,347 $1.25M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 16,155 15,401 $674K
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 20,759 19,105 $611K
93970 4,929 4,470 $514K
99204 Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 2,241 2,144 $159K
64635 2,373 2,008 $127K
80346 5,580 5,439 $126K
80364 5,581 5,440 $108K
64493 2,542 2,174 $84K
80321 5,580 5,439 $76K
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion 2,552 799 $68K
80336 5,580 5,439 $61K
80331 5,579 5,438 $61K
80357 5,581 5,441 $60K
80355 5,583 5,441 $60K
80366 5,581 5,440 $60K
80370 5,581 5,440 $60K
80345 5,580 5,439 $60K
80326 5,580 5,439 $60K
80375 5,568 5,430 $60K
80358 5,581 5,441 $60K
80353 5,579 5,438 $60K
80349 5,581 5,440 $60K
80354 5,579 5,438 $60K
80359 5,579 5,439 $60K
64483 1,515 1,252 $54K
64494 2,525 2,159 $45K
64636 2,383 1,992 $42K
62323 599 509 $36K
81002 14,911 14,085 $26K
97140 Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) 2,487 787 $22K
97113 942 305 $21K
27096 311 293 $19K
97162 448 382 $17K
20552 306 283 $6K
62321 92 78 $6K
64495 293 237 $5K
20610 139 136 $4K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 114 111 $2K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward 94 90 $2K
64490 28 25 $1K
20553 26 26 $714.83
97530 Therapeutic activities, direct patient contact, each 15 minutes 32 24 $522.47
64491 28 25 $520.96
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular 149 94 $486.33
64484 12 12 $414.94
J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg 150 94 $258.20
G0283 Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care 208 72 $221.44